Bausch + Lomb (NYSE:BLCO) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Bausch + Lomb (NYSE:BLCO) announced its quarterly earnings data on Wednesday. The company reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.01), FiscalAI reports. Bausch + Lomb had a negative net margin of 4.21% and a positive return on equity of 3.60%. The firm had revenue of $981.15 million during the quarter, compared to the consensus estimate of $1.37 billion. During the same period last year, the business earned ($0.18) earnings per share. The business’s revenue was up 9.1% compared to the same quarter last year.

Here are the key takeaways from Bausch + Lomb’s conference call:

• Strong Q2 execution: Revenue rose 8% on a constant-currency basis to $1.394 billion, while adjusted EBITDA increased 28% to $246 million and margin expanded to 17.6%. Adjusted operating cash flow reached $161 million, supporting a one-turn reduction in leverage since Investor Day to approximately 4.7x.
• Full-year guidance was raised: Revenue guidance increased by $20 million to $5.440-$5.540 billion, and adjusted EBITDA guidance rose by $15 million to $1.025-$1.075 billion. Management now expects approximately 5.8%-7.7% constant-currency revenue growth and an adjusted EBITDA margin of about 19.1% at the midpoint.
• Surgical momentum accelerated: Surgical revenue grew 16% year over year and 17% versus the pre-recall second quarter of 2024, led by 64% growth in implantables and 175% growth in premium IOLs. Premium products represented 13% of surgical revenue in Q2, up from 9% in 2025, improving mix and margins.
• Pharmaceutical growth remained a key driver: Pharma revenue increased 14%, with MIEBO revenue up 44% to $91 million and XIIDRA up 6% to $87 million. Management cited rising MIEBO prescriptions and Medicare coverage increasing to 88% as sources of continued opportunity in dry eye.
• Pipeline activity is advancing, but remains execution-dependent: The company submitted ELIOS, its implant-free MIGS laser, to the FDA and expects second-half readouts for its dual-action dry-eye and ocular-surface-pain candidates. EnVista Beyond remains on track for submission by year-end and potential approval by the end of 2027, subject to ongoing data review and regulatory processes.

Bausch + Lomb Trading Up 1.2%

Shares of NYSE:BLCO traded up $0.20 during midday trading on Wednesday, hitting $16.81. 212,048 shares of the stock were exchanged, compared to its average volume of 430,833. The stock has a market capitalization of $6.00 billion, a price-to-earnings ratio of -27.11, a P/E/G ratio of 0.50 and a beta of 0.56. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.99 and a current ratio of 1.53. The business’s 50-day moving average price is $15.90 and its 200 day moving average price is $16.43. Bausch + Lomb has a 12 month low of $13.09 and a 12 month high of $18.92.

Key Stories Impacting Bausch + Lomb

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Broad-based growth and raised guidance: Bausch + Lomb reported broad-based second-quarter growth and raised its fiscal 2026 outlook. The company now expects full-year revenue of approximately $5.44 billion to $5.54 billion, compared with a FactSet consensus estimate of $5.47 billion. Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance
• Positive Sentiment: Earnings improved year over year: Quarterly adjusted earnings were reported at $0.16 per share, matching the Zacks consensus estimate and rising from $0.07 a year earlier. The earnings improvement supports the company’s profitability recovery narrative. Bausch + Lomb Q2 Earnings Meet Estimates
• Positive Sentiment: UBS upgrade: UBS upgraded BLCO to “strong-buy” and assigned a $21 price target, implying substantial upside from the reported trading level. The endorsement may increase investor confidence in the company’s growth and execution prospects. UBS Upgrade Report
• Neutral Sentiment: Mixed earnings-data reports: One report listed EPS at $0.15, slightly below consensus, while another reported $0.16 in line with estimates. Reported revenue figures also appear inconsistent, so investors may focus on the company’s official release and conference call for clarification. Bausch + Lomb Earnings Report and Conference Call

Analyst Upgrades and Downgrades

Several research firms have weighed in on BLCO. Deutsche Bank Aktiengesellschaft set a $16.00 target price on Bausch + Lomb in a research note on Thursday, April 30th. Wall Street Zen raised Bausch + Lomb from a “hold” rating to a “buy” rating in a report on Saturday, April 18th. Weiss Ratings raised Bausch + Lomb from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. Evercore set a $17.00 price objective on Bausch + Lomb in a research report on Monday, July 6th. Finally, Citigroup lifted their target price on Bausch + Lomb from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Bausch + Lomb currently has an average rating of “Hold” and an average target price of $18.23.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Glenview Capital Management LLC grew its holdings in Bausch + Lomb by 210.8% during the 2nd quarter. Glenview Capital Management LLC now owns 1,553,855 shares of the company’s stock worth $20,216,000 after acquiring an additional 1,053,855 shares during the last quarter. Davidson Kempner Capital Management LP bought a new position in shares of Bausch + Lomb during the third quarter valued at $14,776,000. Woodline Partners LP raised its stake in shares of Bausch + Lomb by 175.3% during the third quarter. Woodline Partners LP now owns 861,053 shares of the company’s stock valued at $12,976,000 after acquiring an additional 548,230 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Bausch + Lomb by 428.7% in the first quarter. Goldman Sachs Group Inc. now owns 299,671 shares of the company’s stock worth $4,345,000 after purchasing an additional 242,993 shares during the last quarter. Finally, Oaktree Capital Management LP grew its stake in shares of Bausch + Lomb by 4.2% in the fourth quarter. Oaktree Capital Management LP now owns 3,382,739 shares of the company’s stock worth $57,777,000 after purchasing an additional 137,300 shares during the last quarter. Institutional investors own 11.07% of the company’s stock.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.